NCT02638038View on ClinicalTrials.gov

This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 12, 2016

Study Completion Date

December 12, 2016

Conditions
Multiple Sclerosis, Relapsing Remitting
Interventions
DRUG

INT131

INT- 131

Sponsors
All Listed Sponsors
lead

InteKrin Therapeutics, Inc.

INDUSTRY

NCT02638038 - This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years | Biotech Hunter | Biotech Hunter